Philogen entered into a pharma licensing agreement with Pfizer to develop and commercialize empowered antibodies. Read the full story

OPKO Health and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO's long-acting hGH-CTP for the treatment of growth hormone deficiency Read the full story

iTeos Therapeutics in a pharma licensing deal with Pfizer will license the rights to three of its anti-tumor compounds for $24 million, as it attempts to get the backing of a global pharmaceutical firm for the development and commercialization of its IDO1 and TDO2 drug candidates. Read the full story

Spark Therapeutics pharma alliances with big pharma giant Pfizer to develop and commercialize SPK-FIX, a potential treatment for hemophilia B. Read the full story

Merck KGaA has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C Read the full story

Pfizer approved the share repurchase of $11 billion in company stock. Read the full story

Pfizer is signed pharma alliance with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer. Read the full story

Pfizer and Kyowa Hakko Kirin have entered into an pharma alliance agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read the full story

Big pharma,  Pfizer Foundation announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa. Read the full story

Pfizer has signed a pharma deal to promote two new drugs developed by Novartis. Read the full story